Drug Trial Radar · NCT02375880
Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder
Last checked: Nov 19, 2026Latest source record: Aug 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
51
Actual
Start
Jun 2015
Primary completion
Jul 2018
Study completion Jul 2018
Sponsor
- Lead sponsor
- Leap Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 3, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
DKN-01 is a humanized monoclonal antibody (Mab) with neutralizing activity against Dkk-1 and is being developed as an anti-neoplastic agent. This study is designed to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of DKN-01 in combination with gemcitabine and cisplatin in patients with carcinoma primary to the intra- or exta-hepatic biliary system or gallbladder.
Conditions
- Carcinoma of Intrahepatic and Extra-hepatic Biliary System
- Carcinoma of Gallbladder
- Bile Duct Cancer
- Cholangiocarcinoma
Interventions
DKN-01Drug
Administration by intravenous (IV) infusion.
gemcitabineDrug
Administered by IV infusion.
cisplatinDrug
Administered by IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose and dose-limiting toxicities as determined in Part A.Time frame: End of Cycle 1 (Day 21)
- Composite Safety parameters as assessed by new or changing physical examinations, vital signs, electrocardiograms (ECGs), clinical laboratories, concomitant medication reviews, and assessment of adverse events.Time frame: Parts A and B: at a minimum Days 1, 8, 15 of each treatment cycle.
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
University of Southern California
Los Angeles, California
Yale University
New Haven, Connecticut
Massachusetts General Hospital
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
Columbia University Medical Center
New York, New York
University Hospitals, Case Medical Center
Cleveland, Ohio
Cleveland Clinic
Cleveland, Ohio
University of Texas Health Science Center at San Antonio
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.